Clinical Trials Browser

Phase 1/2 × Active not recruiting × Immunotherapy, Adoptive × Clear all

NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06464185 2025-11-18

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

48 enrolled

Lymphoid

Lymphoma, B-Cell

NCT04581473 2025-06-05

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Phase 1/2 Active not recruiting

192 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT03919240 2024-10-24

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Phase 1/2 Active not recruiting

196 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma